Avelumab (Bavencio) — CPB 0916 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0916 covering avelumab (Bavencio) billing, effective October 11, 2025. Here's what your billing team needs to act on now.

Aetna updated its avelumab (Bavencio) coverage policy under CPB 0916, expanding covered indications to include gestational trophoblastic neoplasia, endometrial carcinoma, and thymic carcinoma alongside its existing oncology approvals. The primary billing code is HCPCS J9023 (injection, avelumab, 10 mg), administered via CPT codes 96413–96417 for IV infusion. Precertification is required for all Aetna participating providers before billing J9023 under any covered indication.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Avelumab (Bavencio) — CPB 0916
Policy Code	CPB 0916
Change Type	Modified
Effective Date	October 11, 2025
Impact Level	High — multiple oncology indications covered
Specialties Affected	Oncology, Urology, Gynecologic Oncology, Infusion Centers
Key Action	Update precertification workflows for J9023 across all covered indications before submitting claims

---

Aetna Avelumab (Bavencio) Coverage Criteria and Medical Necessity Requirements 2025

Aetna's avelumab (Bavencio) coverage policy covers six distinct oncology indications under CPB 0916. Each carries specific medical necessity criteria. Miss one criterion and you're looking at a claim denial.

Precertification is mandatory. Call (866) 752-7021 or fax (888) 267-3277 before billing J9023 for any indication. There are no exceptions for participating providers. The site of care utilization management policy also applies — confirm your infusion setting meets Aetna's site-of-service requirements before the patient's first infusion.

Here's what Aetna requires for medical necessity across each covered indication:

Merkel Cell Carcinoma: Avelumab as a single agent for locally advanced, recurrent, or metastatic disease. This is the most straightforward of the six — no combination therapy required, no line-of-therapy restriction.

Renal Cell Carcinoma (RCC): Avelumab must be used in combination with axitinib. Coverage applies to advanced, relapsed, or stage IV RCC with clear cell histology only. First-line treatment only. Note that axitinib (Inlyta) has no specific HCPCS code listed in this policy — bill J9023 for avelumab and confirm axitinib billing separately through your specialty pharmacy workflow.

Urothelial Carcinomas: This is the most complex section of the policy. It covers three distinct subtypes:

#	Covered Indication Copy
1	Bladder cancer — either as subsequent therapy, or as maintenance therapy with no progression on first-line platinum-containing chemotherapy
2	Primary carcinoma of the urethra — same two-pathway structure: subsequent systemic therapy for recurrent/locally advanced/metastatic disease, or maintenance post-platinum
3	Upper GU tract tumors or urothelial carcinoma of the prostate — subsequent therapy for locally advanced or metastatic disease, or maintenance post-platinum

For all three urothelial subtypes, document the line of therapy and prior platinum exposure explicitly in the prior authorization request. Aetna will look for it.

Gestational Trophoblastic Neoplasia (GTN): Avelumab as a single agent for multiagent chemotherapy-resistant disease. Medical necessity requires either recurrent or progressive intermediate trophoblastic tumor (placental site or epithelioid trophoblastic tumor) or high-risk disease. Your gynecologic oncology billing team needs to have this criteria documented before submitting.

Endometrial Carcinoma: Single-agent avelumab for subsequent treatment of recurrent MSI-H or mismatch repair deficient (dMMR) tumors. Biomarker documentation is critical here — prior auth will require proof of MSI-H or dMMR status. Get the pathology report in hand before you submit.

Thymic Carcinoma: Two conditions must both be met for coverage. The first is subsequent therapy, or use in members who cannot tolerate first-line treatment. The source policy summary is truncated — the complete second criterion is not available in the data reviewed here. Review the full policy text at app.payerpolicy.org/p/aetna/0916 before submitting any thymic carcinoma prior auth. Do not assume you have the complete picture from this summary alone.

---

Aetna Avelumab (Bavencio) Exclusions and Non-Covered Indications

The exclusion here is straightforward and absolute. Aetna will not cover avelumab (Bavencio) for any member who experienced disease progression while on any PD-1 or PD-L1 inhibitor therapy.

That list includes nivolumab (Opdivo, J9299), pembrolizumab (Keytruda, J9271), atezolizumab (Tecentriq, J9022), avelumab itself (J9023), and durvalumab (Imfinzi, J9173). If your patient progressed on any of these agents, the prior authorization will be denied regardless of the diagnosis.

The real issue here is documentation timing. If a patient's chart shows prior progression on pembrolizumab and the oncologist is now requesting avelumab, do not submit that prior auth without first confirming the clinical rationale. Your authorization team should flag this in intake screening — before the clinical team spends time completing the SMN form.

---

Coverage Indications at a Glance

---

Aetna Avelumab Billing Guidelines and Action Items 2025

The effective date is October 11, 2025. Claims for newly covered indications submitted before your team has updated its workflows will get denied on prior auth failure — not because the patient doesn't qualify, but because your intake process wasn't ready.

Here's what to do:

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Avelumab (Bavencio) Under CPB 0916

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J9023	HCPCS	Injection, avelumab, 10 mg

CPT Codes for IV Infusion Administration

Full CPT code descriptions for 96413–96417 are not reproduced verbatim in CPB 0916. Verify complete descriptions in the AMA CPT codebook before billing.

ICD-10-CM Diagnosis Codes

The full policy includes 401 ICD-10-CM codes. The source data lists codes across a broad range of malignancy categories. The table below reflects codes as they appear in the source — do not treat these as a confirmed mapping to specific covered indications.

Code	Description Copy
C08.0	Malignant neoplasm of submandibular gland (adenoid cystic carcinoma)
C34.0–C34.59	Malignant neoplasm of bronchus and lung (multiple site-specific codes)
C15.3–C26.9	Malignant neoplasms of digestive organs

Your coding team should pull the full ICD-10 code list from CPB 0916 directly at app.payerpolicy.org/p/aetna/0916 and map each code to the covered indication before October 11, 2025. Submitting J9023 with an ICD-10 code not on Aetna's approved list is a fast path to denial — even if the patient clinically qualifies.

---